EBV EBNA-1 Antibody (3EB8): sc-81584

EBV EBNA-1 Antibody (3EB8) is a mouse monoclonal IgG1 antibody that detects EBV EBNA-1 in human samples by western blotting (WB) and immunoprecipitation (IP). EBV EBNA-1 is a crucial protein expressed in all Epstein-Barr virus-associated tumors, including Burkitt′s lymphoma and nasopharyngeal carcinoma, playing a vital role in the synthesis and maintenance of the Epstein-Barr virus genome. Anti-EBV EBNA-1 antibody (3EB8) recognizes a protein essential for virus-mediated B cell transformation, which is significant given its association with various malignancies. EBV EBNA-1 contains a unique glycine-alanine repeat that is important for function in the viral life cycle, facilitating binding to the viral genome and ensuring replication and persistence within host cells. EBV EBNA-1 interacts with several cellular proteins, including the cellular transcription factor Oct-1, which enhances ability to regulate gene expression. EBV EBNA-1 in infected cells not only contributes to the viral oncogenic process but also serves as a potential biomarker for diagnosing EBV-related diseases. EBV EBNA-1 monoclonal antibody (3EB8) provides researchers with a specific and reliable tool for studying EBV pathogenesis and its role in cancer development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EBV EBNA-1 Antibody (3EB8) References:

1. Epstein-Barr virus nuclear antigen (EBNA)-1 carboxy-terminal and EBNA-4 sequence polymorphisms in nasal natural killer/T-cell lymphoma in the United States.  |  Gaal, K., et al. 2002. Lab Invest. 82: 957-62. PMID: 12118098
2. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.  |  Jones, RJ., et al. 2003. Virology. 313: 663-76. PMID: 12954232
3. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.  |  Hong, M., et al. 2006. J Cancer Res Clin Oncol. 132: 1-8. PMID: 16180023
4. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).  |  Lu, F., et al. 2010. Virol J. 7: 262. PMID: 20929547
5. The Epstein-Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins.  |  Coppotelli, G., et al. 2013. Nucleic Acids Res. 41: 2950-62. PMID: 23358825
6. EBNA1-specific luminescent small molecules for the imaging and inhibition of latent EBV-infected tumor cells.  |  Jiang, L., et al. 2014. Chem Commun (Camb). 50: 6517-9. PMID: 24821080
7. Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites.  |  Jones, CH., et al. 1989. J Virol. 63: 101-10. PMID: 2535719
8. Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.  |  Zhou, Y., et al. 2016. Mult Scler. 22: 1655-1664. PMID: 26819262
9. EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.  |  Erdur, H., et al. 2016. J Neuroimmunol. 294: 14-7. PMID: 27138093
10. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.  |  Khanna, R., et al. 1997. Int Immunol. 9: 1537-43. PMID: 9352359

The preferred EBV EBNA-1 antibody is EBV EBNA-1 Antibody (1EB12): sc-81581.